interferon beta-1b / University of Hong Kong - LARVOL DELTA

A prospective follow-up on thyroid function, thyroid autoimmunity and long COVID among 250 COVID-19 survivors. (PubMed, Endocrine) - "Over 6 months, most abnormal TFTs in acute COVID-19 resolved, with no significant incident thyroid dysfunction. SARS-CoV-2 infection did not lead to change in thyroid autoimmunity, while interferon treatment was associated with modest increase in anti-thyroid antibody titres. Thyroid function and anti-thyroid antibodies did not play a significant role in long COVID."

Journal • Endocrine Disorders • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Early treatment of high-risk hospitalized COVID-19 patients with a combination of interferon beta-1b and remdesivir: a phase 2 open-label randomized controlled trial. (PubMed, Clin Infect Dis) - "Early treatment with interferon beta-1b and remdesivir was safe and better than remdesivir only in alleviating symptoms, shorten viral shedding and hospitalization with earlier seropositivity in high-risk COVID-19 patients."

Journal • P2 data • Infectious Disease • Novel Coronavirus Disease

The Impact of Interferon Beta-1b Therapy on Thyroid Function and Autoimmunity Among COVID-19 Survivors. (PubMed, Front Endocrinol (Lausanne)) - "IFN for COVID-19 was associated with modest increases in anti-thyroid antibody titres, and a trend of more incident anti-TPO positivity and abnormal TFTs during convalescence. Our findings suggest that clinicians monitor the thyroid function and anti-thyroid antibodies among IFN-treated COVID-19 survivors, and call for further follow-up studies regarding the clinical significance of these changes."

Journal • Endocrine Disorders • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

IFN-beta 1b and Remdesivir for COVID19 (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: The University of Hong Kong

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease

Double Therapy With IFN-beta 1b and Hydroxychloroquine (clinicaltrials.gov) - P2; N=60; Completed; Sponsor: The University of Hong Kong; Recruiting ➔ Completed; Trial completion date: Jul 2022 ➔ Jul 2020; Trial primary completion date: Mar 2022 ➔ Jul 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

IFN Beta-1b and Ribavirin for Covid-19 (clinicaltrials.gov) - P2; N=96; Recruiting; Sponsor: The University of Hong Kong

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease

Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19 (clinicaltrials.gov) - P2; N=81; Recruiting; Sponsor: The University of Hong Kong

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease

Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19 (clinicaltrials.gov) - P2; N=81; Recruiting; Sponsor: The University of Hong Kong; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease

Double Therapy With IFN-beta 1b and Hydroxychloroquine (clinicaltrials.gov) - P2; N=80; Recruiting; Sponsor: The University of Hong Kong

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease

Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment (clinicaltrials.gov) - P2; N=127; Completed; Sponsor: The University of Hong Kong; Recruiting ➔ Completed; N=70 ➔ 127; Trial completion date: Jul 2022 ➔ Mar 2020; Trial primary completion date: Jan 2022 ➔ Mar 2020

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease